Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 809 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
Report on the treasury shares buy-back plan of Diasorin S.p.A. – Period 18/05/2026 – 22/05/2026
Regulatory Filings
2026-05-22 Italian
Informativa sul programma di acquisto di azioni proprie di Diasorin S.p.A. - Periodo 18/05/2026 – 22/5/2026
Regulatory Filings
2026-05-22 Italian
Diasorin 2026 Investor Day Presentation
Investor Presentation Classification · 93% confidence The document is a slide deck titled “2026 Investor Day” for Diasorin, containing forward‐looking statements, strategic overview, market trends, and other presentation materials targeted at investors. It lacks full audited financial statements or formal regulatory filings and is clearly an investor presentation rather than an annual or interim report, earnings release, or regulatory notice.
2026-05-20 English
Diasorin Board of Directors approves the 2026-2030 Business Plan
Investor Presentation Classification · 85% confidence The document is a regulated press release issued by Diasorin announcing that the Board of Directors has approved the new 2026–2030 Business Plan. It contains detailed forward-looking guidance (revenue, EBITDA, cash flow), growth drivers by business line, strategic priorities, and references to an upcoming Investor Day with supporting slides. This aligns with an Investor Presentation (IP) rather than a simple earnings release or general regulatory notice. Therefore, it should be classified as an Investor Presentation.
2026-05-20 English
Il Consiglio di Amministrazione di Diasorin approva il Piano Industriale 2026-2030
Regulatory Filings Classification · 75% confidence The document is a press release disclosing that the Board of Directors of Diasorin approved the 2026–2030 Industrial Plan, including guidance and strategic drivers. It is not an AGM presentation, financial report, earnings release, or other specific category. It is a general regulated disclosure (‘Informazione Regolamentata’) without substantive financial statements or a formal report itself. Therefore, it falls into the fallback category of Regulatory Filings (RNS).
2026-05-20 Italian
Report on the treasury shares buy-back plan of Diasorin S.p.A. – Period 11/05/2026 – 15/05/2026
Regulatory Filings
2026-05-15 Italian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.